Tagging out

A protein degradation method by Bradner, Gray could improve target validation

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray have demonstrated in a paper published in Nature Chemical Biology that targeted protein degradation can be used to create preclinical models that offer better control over a protein’s expression than traditional genetic or pharmacological approaches.

Bradner is president of the Novartis Institutes for BioMedical Research (NIBR). Gray is a professor of cancer biology

Read the full 627 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers